Does Wegovy Cause Bone Loss? What the Evidence Shows

Why weight loss itself affects bone, and where semaglutide fits in

A common misconception is that bone loss on Wegovy is caused by the drug acting on bones directly. The reality is subtler. Most of the bone density change seen during semaglutide treatment appears to follow the same path as bone loss during any significant calorie deficit: when body mass falls, the mechanical load on the skeleton falls too, and bone remodels to match. Less load means a slower rate of new bone formation relative to resorption.

There is also a separate question about whether GLP-1 receptor agonists have any direct effect on bone metabolism. GLP-1 receptors are present in bone tissue, and some researchers have proposed the drug might influence bone turnover independently of weight change. Evidence here is preliminary and mixed. What the trials do consistently show is modest reductions in bone mineral density markers, particularly at the hip, over the course of treatment, and our page on Wegovy and bone loss explores that evidence in more detail. The NHS patient information page for semaglutide notes bone pain and, in clinical studies, changes to bone metabolism as outcomes being monitored.

No large randomised trial has yet reported a statistically significant increase in actual fracture events attributable to Wegovy specifically, which is reassuring, but absence of evidence is not the same as evidence of absence, and longer-term data are still maturing.

Who should think most carefully about this before deciding

For most adults starting Wegovy, the bone question is one to note and manage rather than a reason to rule out treatment. For some groups, though, it deserves a longer conversation with a prescriber.

People already living with osteoporosis or osteopenia are starting with lower bone reserve, so even a modest treatment-related reduction carries more clinical weight. Post-menopausal women are in a similar position: oestrogen decline already accelerates bone turnover, and adding rapid weight loss to that backdrop is something a prescriber should explicitly assess. The same thinking applies to anyone with a history of fragility fractures, long-term corticosteroid use, or a family history of osteoporosis.

Age matters too. Older adults generally lose weight more slowly on GLP-1 treatment and may also lose more lean mass proportionally, which compounds the mechanical unloading effect on bone. If you're curious about how semaglutide brings about weight loss in the body, our dedicated page covers the mechanisms in plain terms.

Younger adults with healthy bone density and no risk factors can reasonably weigh the bone question alongside the well-established cardiovascular and metabolic benefits of sustained weight reduction. For many, the net health calculation still favours treatment, but that calculation belongs with a clinician, not a general article.

Practical steps that protect bone while on treatment

The good news is that several of the most effective bone-protective strategies are also just good practice during any weight-loss programme. They are worth knowing before you start.

Protein adequacy is probably the most underestimated factor. Appetite suppression on Wegovy can make it easy to eat far too little protein, which accelerates both muscle and bone loss. Most guidance points to at least 1.2 g of protein per kilogram of body weight daily, though personal targets depend on the individual, your prescriber or a dietitian can give a more precise figure. Our page on whether Wegovy causes muscle loss covers that parallel concern in more detail, since muscle and bone health are closely linked.

Resistance exercise is the other major lever. Lifting, pushing or pulling against load stimulates bone formation directly, regardless of weight change. Walking alone does not provide the same stimulus.

Calcium and vitamin D sufficiency matter throughout. If your dietary intake is low (especially if appetite is reduced on treatment) supplementation is worth discussing with a prescriber. Bone density scanning (DEXA) is available on the NHS for people at elevated risk and gives a baseline that makes monitoring meaningful.

You can read more about the broader range of side effects and effects associated with this medicine on our Wegovy side effects overview.

What the current evidence can and cannot tell you

The STEP trial programme, which underpins Wegovy's licence, ran for 68 weeks. That is long enough to observe early changes in bone turnover markers, but not long enough to capture fracture outcomes reliably, since fractures from low bone density typically accumulate over years and decades. Longer post-marketing studies are ongoing, and regulators continue to monitor the signal.

What we can say with reasonable confidence: bone density reductions during Wegovy treatment appear modest and consistent with those seen in calorie-restricted weight loss generally, and if you want to understand whether and how Wegovy actually causes weight loss, our dedicated page sets out the evidence clearly. Fracture risk attributable specifically to the medicine remains unproven at meaningful scale. The NICE appraisal of semaglutide (TA875) acknowledges the bone health data as one factor the committee considered, alongside the substantial cardiovascular and metabolic benefits in the eligible population.

What this means practically is that the decision is not binary. Bone health is one variable in a clinical conversation that also includes your current weight, comorbidities, cardiovascular risk, quality of life, and what alternatives exist. If you'd like to understand more about what Wegovy treatment involves before having that conversation, our Wegovy overview sets out the full picture. For those thinking about whether treatment might be right for them, the free consultation at nume is the place to start that discussion with a prescriber who can assess your individual circumstances.